"label","description","uuid:ID","text","id","name","instanceType"
"","Main objective","83e890b3-47c2-4854-91bd-b4b3221eb4b9","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","Objective_1","OBJ1","OBJECTIVE"
"","Safety","832df32a-be68-4f52-836d-80c972b50214","To document the safety profile of the xanomeline TTS.","Objective_2","OBJ2","OBJECTIVE"
"","Behaviour","c7e2ad20-3343-4ed5-a3e4-3f61f4114ba5","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","Objective_3","OBJ3","OBJECTIVE"
